Figure 6

WFA has anabolic effect in osteopenic bones. (a and b). Oral supplementation of WFA to OVx mice increases mineralized nodule formation in BMCs as assessed by alizarin red-S staining. Values represent Mean±S.E. of three independent experiments n=3. *P<0.05, **P<0.01 as compared with OVx vehicle group. (c and d). WFA supplementation increases mineral apposition rate and bone formation rate in OVx mice. Dynamic histomorphometric parameters (MAR and BFR) at the femur mid-diaphysis was calculated from the double fluorochrome labeling experiments in various groups.Values represent Mean±S.E. of three independent experiments n=3. ***P<0.001 compared with OVx vehicle group. ^aP<0.001 when 10 mg/kg/day dose compared with 1 mg/kg/day. ^dP<0.001 when 10 mg/kg/day dose compared with 5 mg/kg/day. (e) WFA supplementation restores the trabecular micro-architecture of the femur epiphysis. Representative μCT images of the femur epiphysis of various experimental groups. (f–i) μCT analysis of various trabecular parameters of the femur epiphysis, including BV/TV, Tb.No, Tb.Th and SMI are presented. All values are expressed as mean±S.E.M. *P<0.05, **P<0.01, ***P<0.001 ^aP<0.001 when 10 mg/kg/day dose compared with 1 mg/kg/day. ^dP<0.001 when 10 mg/kg/day dose compared with 5 mg/kg/day dose, ^fP<0.05 when 10 mg/kg/day dose compared with 5 mg/kg/day dose, ^gP<0.05 when 10 mg/kg/day dose compared with Ald 3 mg/kg/day dose, ⁱP<0.05 when 10 mg/kg/day dose compared with Bzb 0.3 mg/kg/day dose WFA supplementation has a significant restorative effect on the trabecular micro-architecture of L5 vertebrae. Figure shows representative μCT images of various treated group. (k–n) Trabecular parameters of L5 vertebrae of various treatment groups. All values are expressed as mean±S.E.M. *P<0.05, **P<0.01, ***P<0.001 compared with OVx group, ^bP<0.01 when 10 mg/kg/day dose compared with 1 mg/kg/day dose, ⁱP<0.05 when 10 mg/kg/day dose compared with Bzb 0.3 mg/kg/day dose